Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake

Yu Wu¹, Fei Fang²

Affiliations

¹ Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, USA.
² Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT 06510, USA. Electronic address: fei.fang@yale.edu.

Comment

Yu Wu et al. Lancet Gastroenterol Hepatol. 2024 May.

. 2024 May;9(5):409.

doi: 10.1016/S2468-1253(24)00048-7.

Yu Wu¹, Fei Fang²

¹ Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, USA.
² Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT 06510, USA. Electronic address: fei.fang@yale.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K, Hansen JK, Villesen I, Bech K, Wernberg C, Andersen P, Lindvig KP, Tsochatzis EA, Thiele M, Rinella ME, Krag A; GALAXY consortium. Israelsen M, et al. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):218-228. doi: 10.1016/S2468-1253(23)00443-0. Epub 2024 Jan 11. Lancet Gastroenterol Hepatol. 2024. PMID: 38218202